Cipla vs Aurobindo Pharma: Which Stock Should You Track
- July 31, 2026
- Posted by: Neeraj Pandey
- Category: News
Cipla vs Aurobindo Pharma: a leading Indian pharmaceutical company with respiratory category leadership vs a leading Indian generics exporter with a global manufacturing footprint. Cipla sector: Ph…
Cipla vs Aurobindo Pharma is a comparison investors search for because the two companies represent genuinely different positions within Pharmaceuticals. This Cipla vs Aurobindo Pharma breakdown goes beyond generic labels and looks at real numbers: reach, products, the latest results each company has declared, and how each stock is positioned today. Understanding Cipla vs Aurobindo Pharma this way is more useful than a surface-level label, because it shows where each company actually stands rather than how it describes itself.
Cipla vs Aurobindo Pharma: Reach and Market Position
In the Cipla vs Aurobindo Pharma comparison, Cipla stands out for a leading Indian pharmaceutical company with a strong respiratory and India-business franchise, maintaining a net cash position of over Rs 9,000 crore. This scale gives Cipla a distinct position within Pharmaceuticals that shapes how it competes.
Click Here – Get Free Investment Predictions
Aurobindo Pharma, on the other hand, is built around a Hyderabad-based drugmaker exporting to over 150 countries through 27 global manufacturing and packing facilities. Comparing Cipla vs Aurobindo Pharma on reach alone shows two different growth strategies, not a single verdict.
Cipla vs Aurobindo Pharma: Key Products and Business Mix
Cipla’s business runs on respiratory therapies, generic drugs, oncology treatments, and One India branded formulations. This product mix is central to any Cipla vs Aurobindo Pharma comparison, since it explains where each company’s revenue actually comes from.
Aurobindo Pharma instead leans on generic drugs, active pharmaceutical ingredients, and biocatalysts through its AuroZymes division. The Cipla vs Aurobindo Pharma product comparison shows these are genuinely different businesses, not just different brand names in the same category.
Cipla vs Aurobindo Pharma: Latest Results
Looking at real numbers rather than claims, Cipla’s latest disclosed results show Q1 FY27 net profit of Rs 785.55 crore, down 39.2% YoY, on revenue of Rs 7,119.28 crore, up 2.33%, with the decline driven by margin contraction and new labour-code-related costs even as India business revenue hit a record Rs 3,452 crore; FY26 revenue was a record Rs 28,000 crore. This is the clearest evidence available for the Cipla vs Aurobindo Pharma comparison on Cipla’s side.
Aurobindo Pharma’s latest disclosed results show FY2025 (latest full-year figures available) revenue of Rs 31,724 crore; prior-year quarterly results have shown swings tied to US sales and destocking cycles, with profit ranging from double-digit growth to double-digit declines across recent quarters. Weighing Cipla vs Aurobindo Pharma on actual results, rather than headline positioning, is what separates a useful comparison from a generic one.
Compare Cipla and Aurobindo Pharma Fundamentals on the Univest Screener
Cipla vs Aurobindo Pharma: Stock and Valuation
On the market side, Cipla is described as: Maintained a strong net cash position despite the profit decline. Aurobindo Pharma is described as: Holds USFDA, UK MHRA and other major regulatory approvals across its facility network. The Cipla vs Aurobindo Pharma valuation gap often reflects how the market is pricing each company’s growth and risk profile differently.
Cipla vs Aurobindo Pharma: Quick Comparison Table
| Parameter | Cipla | Aurobindo Pharma |
|---|---|---|
| Sector | Pharmaceuticals | Pharmaceuticals |
| Market position | a leading Indian pharmaceutical company with respiratory category leadership | a leading Indian generics exporter with a global manufacturing footprint |
| Reach | a leading Indian pharmaceutical company with a strong respiratory and India-business franc | a Hyderabad-based drugmaker exporting to over 150 countries through 27 global manufacturin |
| Latest results | Q1 FY27 net profit of Rs 785.55 crore, down 39.2% YoY, on revenue of Rs 7,119.28 crore, up 2.33%, wi | FY2025 (latest full-year figures available) revenue of Rs 31,724 crore; prior-year quarterly results |
Conclusion
Cipla vs Aurobindo Pharma ultimately comes down to two companies solving similar problems in different ways. Cipla brings a leading Indian pharmaceutical company with respiratory category leadership, while Aurobindo Pharma brings a leading Indian generics exporter with a global manufacturing footprint. Investors weighing Cipla vs Aurobindo Pharma should track both companies’ upcoming results and valuation gap rather than picking a side on reputation alone. This Cipla vs Aurobindo Pharma breakdown is a starting point, not a final verdict.
Download the Univest iOS App or Univest Android App to track Cipla and Aurobindo Pharma live price and get daily stock recommendations.
Disclaimer: Data and figures in this article are sourced from publicly available information, including company results filings and exchange data, and are current as of the time of writing. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the main difference between Cipla and Aurobindo Pharma?
Ans. The main difference in the Cipla vs Aurobindo Pharma comparison lies in scale and business mix. Cipla is built on a leading Indian pharmaceutical company with respiratory category leadership, while Aurobindo Pharma is positioned around a leading Indian generics exporter with a global manufacturing footprint.
How do Cipla and Aurobindo Pharma’s latest results compare?
Ans. Comparing Cipla vs Aurobindo Pharma on latest disclosed results: Cipla reported Q1 FY27 net profit of Rs 785.55 crore, down 39.2% YoY, on revenue of Rs 7,119.28 crore, up 2.33%, with the decline driven by margin contract, while Aurobindo Pharma reported FY2025 (latest full-year figures available) revenue of Rs 31,724 crore; prior-year quarterly results have shown swings tied to US sales and .
What sector do Cipla and Aurobindo Pharma operate in?
Ans. Cipla operates in Pharmaceuticals and Aurobindo Pharma operates in Pharmaceuticals. Even where the sectors overlap, the Cipla vs Aurobindo Pharma comparison shows different product mixes and market positions.
Should I invest in Cipla or Aurobindo Pharma?
Ans. Both Cipla and Aurobindo Pharma have distinct strengths within their space. Investors comparing Cipla vs Aurobindo Pharma should review the latest quarterly results, valuation and their own risk profile, and consult a financial advisor before deciding.
What are the key products of Cipla?
Ans. Cipla’s key products and business lines include respiratory therapies, generic drugs, oncology treatments, and One India branded formulations.
What are the key products of Aurobindo Pharma?
Ans. Aurobindo Pharma’s key products and business lines include generic drugs, active pharmaceutical ingredients, and biocatalysts through its AuroZymes division.
How do Cipla and Aurobindo Pharma compare on market position?
Ans. On market position, Cipla holds a leading Indian pharmaceutical company with respiratory category leadership, while Aurobindo Pharma holds a leading Indian generics exporter with a global manufacturing footprint. The Cipla vs Aurobindo Pharma comparison shows both companies lead in different ways rather than one being universally ahead.
